<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22032" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Gallbladder Carcinoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Menon</surname>
            <given-names>Gopal</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Babiker</surname>
            <given-names>Hani M.</given-names>
          </name>
          <aff>University of Arizona Cancer Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gopal Menon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hani Babiker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22032.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Gallbladder carcinoma is a rare malignancy but constitutes nearly half of all biliary tract cancers. The prognosis is grim due to factors like aggressive tumor biology, complex anatomical location, and advanced stage at diagnosis. Surgical resection followed by adjuvant therapy offers a chance for cure in early-stage disease, while palliative chemotherapy is the mainstay for locally advanced and metastatic disease. Various chemotherapeutic regimens are employed based on clinical trials, with gemcitabine and cisplatin being standard first-line options for fit patients. Regular surveillance and close monitoring are crucial for long-term management, with clinical trials recommended for patients with advanced, unresectable disease. This activity for healthcare professionals reviews the etiology, epidemiology, pathophysiology, histopathological findings, and evaluation of gallbladder carcinoma, including diagnostic challenges with delayed presentations, treatment modalities, chemotherapy regimens, surveillance protocols, and implementing an appropriate interprofessional management approach to improve patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients with possible gallbladder carcinoma based on their clinical history and presentation.</p></list-item><list-item><p>Apply current staging systems to patients with gallbladder carcinoma.</p></list-item><list-item><p>Select the most appropriate therapeutic regimen for a patient with gallbladder carcinoma.</p></list-item><list-item><p>Develop and implement&#x000a0;interprofessional team strategies to improve care coordination and outcomes for&#x000a0;patients with gallbladder carcinoma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22032&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22032">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22032.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Gallbladder carcinoma is a rare malignancy but represents almost 50% of all biliary tract cancer.<xref ref-type="bibr" rid="article-22032.r1">[1]</xref>&#x000a0;Most tumors are adenocarcinomas, with squamous, adenosquamous, and neuroendocrine tumors being less common. Gallbladder neoplasms are more prevalent in women, with marked geographic variation in incidence.&#x000a0;Most gallbladder tumors arise from the mucosal lining as the gallbladder lacks a submucosal layer and subsequently spread through the thin muscularis early in the disease course. Early symptoms may be similar to biliary colic or cholecystitis and might account for the late stage of diagnosis associated with this cancer. Consequently, tumors are often nonresectable at diagnosis.</p>
        <p>Surgical resection is the treatment of choice, and not infrequently, a focus of early-stage carcinoma may be incidentally detected in patients undergoing cholecystectomy. In contrast to other biliary carcinomas, gallbladder carcinoma is associated with a higher rate of distant metastatic disease and may derive more benefit from chemotherapy. Chemotherapy is used in the adjuvant setting and palliative care.<xref ref-type="bibr" rid="article-22032.r2">[2]</xref> The overall prognosis is poor, with 5-year survival rates of &#x0003c;20%. Recent advances in studying the genetic drivers and molecular profile of these tumors have heralded the use of targeted agents, hopefully improving the prognosis of this disease.<xref ref-type="bibr" rid="article-22032.r3">[3]</xref></p>
      </sec>
      <sec id="article-22032.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>
<bold>Gallbladder Carcinoma Risk Factors</bold>
</p>
        <p>Chronic gallbladder inflammation is the most common pathogenic pathway associated with gallbladder carcinoma.<xref ref-type="bibr" rid="article-22032.r4">[4]</xref>&#x000a0;This chronic inflammation underlies many of the following risk factors for the development of this neoplasm.</p>
        <list list-type="bullet">
          <list-item>
            <p>Cholelithiasis: The strongest correlation to developing gallbladder cancer is cholelithiasis. Gallstones cause a 4- to 5-fold increase in the prevalence of cancer. The risk increases with increases with gallstone size and chronicity of inflammation. Stones greater than 3 cm in size are most strongly associated with cancer, especially when symptomatic.<xref ref-type="bibr" rid="article-22032.r5">[5]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Gallbladder calcification: Also known as porcelain gallbladder (see <bold>Image</bold>. Porcelain Gallbladder), this is a condition where the inner gallbladder wall is encrusted with calcium.&#x000a0;Porcelain gallbladder is very rare&#x000a0;and was previously believed to be associated with gallbladder malignancies. However, the current opinion is that the risk of malignancy is small.<xref ref-type="bibr" rid="article-22032.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Gallbladder polyps: Approximately 4% to 7% of the population may develop&#x000a0;gallbladder&#x000a0;polyps, the incidence of which increases with age.&#x000a0;True adenomatous&#x000a0;gallbladder&#x000a0;polyps&#x000a0;are considered neoplastic, unlike inflammatory polyps and pseudopolyps. Adenomatous gallbladder polyps are rare and often associated with gallstones. The malignant potential increases&#x000a0;with polyps measuring greater than 1 cm; malignant&#x000a0;polyps&#x000a0;tend to be solitary and larger than 2 cm in diameter.<xref ref-type="bibr" rid="article-22032.r6">[6]</xref><xref ref-type="bibr" rid="article-22032.r7">[7]</xref><xref ref-type="bibr" rid="article-22032.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Congenital biliary cysts and abnormal pancreaticobiliary anatomy&#x000a0;<xref ref-type="bibr" rid="article-22032.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Areas with endemic <italic toggle="yes">Salmonella</italic> Typhi and <italic toggle="yes">Helicobacter pylori</italic> infection&#x000a0;<xref ref-type="bibr" rid="article-22032.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Primary sclerosing cholangitis and inflammatory bowel disease&#x000a0;<xref ref-type="bibr" rid="article-22032.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Extrinsic carcinogens, including medications (eg, methyldopa, isoniazid), work exposure (eg, methylcellulose, radon), and lifestyle (eg, cigarette smoking, obesity, high carbohydrate intake)&#x000a0;<xref ref-type="bibr" rid="article-22032.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22032.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Gallbladder adenocarcinoma is the most common biliary tumor, although overall a relatively rare cancer. More than 50% of cases are detected incidentally at the time of cholecystectomy.<xref ref-type="bibr" rid="article-22032.r9">[9]</xref> In 2023, roughly 5000 new cases of gallbladder cancer were diagnosed, with a 5-year overall survival rate of 19%. The incidence of gallbladder carcinoma increases with age and is reported to be more common in women. Worldwide, the incidence of gallbladder cancer is high in specific&#x000a0;populations due to the high prevalence of gallstones and chronic gallbladder infections; according to the 2018 GLOBOCAN data, Bolivia, Chile, and parts of the Indian subcontinent have the highest rates.<xref ref-type="bibr" rid="article-22032.r10">[10]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22032.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Chronic inflammation is the primary oncogenic driver of gallbladder carcinoma. Toxins and direct injury may be additional pathophysiologic factors. The mutational profile of gallbladder adenocarcinoma most commonly involves K-<italic toggle="yes">ras,</italic>&#x000a0;<italic toggle="yes">TP53, CDKN2a,</italic>&#x000a0;and c-<italic toggle="yes">erb-</italic>b2 mutations. In addition, gene promoter hypermethylation has been increasingly identified as a pathogenic contributor. In a subset of patients, advancement to cancer may follow a pathway similar to cancer that arises from premalignant lesions in other organs, such as colon cancer (ie, gallbladder adenomas), which progresses from dysplasia to invasive cancers.<xref ref-type="bibr" rid="article-22032.r11">[11]</xref>&#x000a0;The heterogeneity in genetic drivers is further evidence of the complex pathogenesis of gallbladder carcinoma.<xref ref-type="bibr" rid="article-22032.r12">[12]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22032.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Gallbladder adenocarcinomas are often associated with cholelithiasis or gallbladder polyps on gross examination. Direct extension through the serosa into the liver or onto the peritoneal surface may be present. The tumor may be polyploid or infiltrative, often with the adjacent gallbladder wall thickening. Chronic cholecystitis is common. When diagnosed incidentally on cholecystectomy specimens, the malignant lesions may be subtle and require careful examination to make a diagnosis.<xref ref-type="bibr" rid="article-22032.r13">[13]</xref>&#x000a0;</p>
        <p>Microscopically, most tumors are adenocarcinomas, with cuboidal or columnar epithelial gland formation varying by the degree of tumor differentiation (see <bold>Image</bold>. Gallbladder Adenomyomatosis). Desmoplasia is a common feature. Variants include the intestinal type, which resembles colon adenocarcinoma; the mucinous type, which has over 50% extracellular mucin; and other rarer subtypes.<xref ref-type="bibr" rid="article-22032.r14">[14]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22032.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Early-stage gallbladder carcinoma is often found incidentally during surgery, as it is typically asymptomatic. When symptoms do occur, they are frequently nonspecific and similar to those of other gallbladder conditions. Patients with larger lesions may experience symptoms such as biliary colic or cholecystitis. Since many gallbladder tumors are found alongside cholelithiasis and cholecystitis, it can be difficult to distinguish between the symptoms of these conditions. Advanced stages of gallbladder cancer can cause vague symptoms such as abdominal pain, nausea, weakness, anorexia, loss of appetite, weight loss, and jaundice. More severe cases may lead to biliary obstruction or fistulization to the biliary tree or the duodenum, which are signs of advanced disease.&#x000a0;</p>
        <p>The physical examination of a patient with gallbladder carcinoma may reveal tenderness in the right upper quadrant, a positive Murphy sign, jaundice, or a Courvoisier sign (a nontender, palpable gallbladder with jaundice) may be present. Hepatomegaly, a palpable abdominal mass, ascites, and bowel obstruction are signs that indicate metastatic disease.<xref ref-type="bibr" rid="article-22032.r15">[15]</xref></p>
      </sec>
      <sec id="article-22032.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>When gallbladder carcinoma is suspected, patients should undergo laboratory evaluations, including a complete blood count, basic chemistry panel, and liver function tests. A right upper quadrant ultrasound is usually the first step in evaluating biliary pathology and may demonstrate gallbladder tumors, polyps, cholelithiasis, cholecystitis, or biliary obstruction (see <bold>Image</bold>. Gallbladder Stone). Further imaging with computed tomography (CT), magnetic resonance imaging (MRI), MR cholangiopancreatography (MRCP), endoscopic ultrasound (EUS), or positron emission tomography/computed tomography (PET/CT) scans may be indicated if the suspicion for gallbladder carcinoma is high.&#x000a0;</p>
        <p>CT provides excellent anatomic detail and can identify local invasion, lymphadenopathy, and metastatic disease (see <bold>Image</bold>. Gallbladder Carcinoma). MRI&#x000a0;can help assess disease extent more accurately and identify unresectable&#x000a0;tumors&#x000a0;with hepatoduodenal ligament invasion, vasculature encasement, and lymph node involvement.<xref ref-type="bibr" rid="article-22032.r16">[16]</xref>&#x000a0;Both modalities are insensitive in discriminating benign from malignant lymph nodes &#x0003c;10 mm in size. EUS&#x000a0;is more accurate than&#x000a0;ultrasound, CT, and MRI, especially in detecting lymphadenopathy. EUS also allows suspicious lymph nodes to be sampled. Most gallbladder cancers are 18F-fluorodeoxyglucose avid by PET/CT, and PET/CT can help identify occult metastatic disease.&#x000a0;</p>
        <p>Tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9), are frequently elevated but considered nondiagnostic due to lack of specificity (CA 19-9 92.7% versus CEA 79.2%) and sensitivity (CA 19-9 50% versus CEA 79.4%). Baseline CEA and CA 19-9 tests are useful for monitoring response to therapy.<xref ref-type="bibr" rid="article-22032.r17">[17]</xref>&#x000a0;In patients with suspected locally advanced disease but without any evidence of distant metastatic disease, a diagnostic laparoscopy may be indicated to help inform systemic therapy.</p>
      </sec>
      <sec id="article-22032.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The only definitive treatment for gallbladder carcinoma is surgery. Chemotherapy and radiation therapy are used as adjuncts after surgery or in patients with unresectable or advanced metastatic tumors.&#x000a0;</p>
      </sec>
      <sec id="article-22032.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses that should also be considered when evaluating gallbladder carcinoma, include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acalculous cholecystitis</p>
          </list-item>
          <list-item>
            <p>Ampullary carcinoma</p>
          </list-item>
          <list-item>
            <p>Bile duct strictures</p>
          </list-item>
          <list-item>
            <p>Bile duct tumors</p>
          </list-item>
          <list-item>
            <p>Biliary colic</p>
          </list-item>
          <list-item>
            <p>Biliary disease</p>
          </list-item>
          <list-item>
            <p>Biliary obstruction</p>
          </list-item>
          <list-item>
            <p>Cholangitis</p>
          </list-item>
          <list-item>
            <p>Cholecystitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22032.s11" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>Surgical treatment of gallbladder carcinoma depends on the tumor stage and requires complete surgical excision with negative margins. Staging laparoscopy is recommended in patients with bulky tumors; this evaluation may identify radiologically occult metastatic disease.<xref ref-type="bibr" rid="article-22032.r18">[18]</xref><xref ref-type="bibr" rid="article-22032.r19">[19]</xref>&#x000a0;Laparoscopy may also be considered when a gallbladder carcinoma is identified incidentally and the pathologic stage is greater than T1a. While historically, excision of the laparoscopic port sites was recommended in patients undergoing reoperation for gallbladder carcinoma after initial laparoscopic cholecystectomy, this is no longer recommended.<xref ref-type="bibr" rid="article-22032.r20">[20]</xref>&#x000a0;The following surgical procedures are recommended based on gallbladder carcinoma staging:</p>
        <list list-type="bullet">
          <list-item>
            <p>T1a tumors:&#x000a0;Tumors confined to the mucosa require only a cholecystectomy. This typically occurs when a gallbladder carcinoma is incidentally detected during pathologic examination.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>T1b, T2, and T3 tumors: Patients with more advanced disease should undergo a radical cholecystectomy and portal lymphadenectomy.
<list list-type="bullet"><list-item><p>A radical cholecystectomy typically involves the en-bloc resection of the gallbladder with a limited resection of the adjacent segments 4b and 5. Typically, patients who have tumor invasion into the liver need more extensive liver resections to obtain negative margins. However, resections beyond segments 4b and 5 are typically not indicated and should be performed only in the appropriate clinical situations where negative margins are likely to impact survival. For example, extended hepatic resection in cases with bulky lymphadenopathy is unlikely to be beneficial. Routine extended hepatic and biliary resections increase morbidity and mortality without any survival benefit. Bile duct excision and biliary reconstruction may be indicated if the cystic duct margins are persistently positive or if lymph nodes along the extrahepatic bile duct are adherent.&#x000a0;</p></list-item><list-item><p>Portal lymphadenectomy involves removing all the lymph nodes along the hepatoduodenal ligament, the porta hepatis, and the retroduodenal region. Enlarged lymph nodes beyond these areas should be considered metastatic.&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22032.s12" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>
<bold>Adjuvant Therapy</bold>
</p>
        <p>Radiotherapy (RT) may be used in the adjuvant setting for gallbladder carcinoma.<xref ref-type="bibr" rid="article-22032.r21">[21]</xref>&#x000a0;In patients who undergo a complete resection with microscopically negative margins, RT is not indicated. However, in patients with a microscopically positive or grossly positive surgical margin,&#x000a0;chemoradiotherapy is generally used to reduce local recurrence. The radiation dose depends on the tumor location, the tolerance of surrounding organs, and underlying liver function. Image-guided techniques, such as 3-dimensional conformal and intensity-modulated RT, improve targeting and reduce toxicity. The radiation field should include the operative bed and the regional lymph nodes (eg, portal, celiac, para-aortic, superior mesenteric artery). Typical doses range from 40 to 45 Gy to the lymph nodes and 55 to 60 Gy to the tumor site.<xref ref-type="bibr" rid="article-22032.r22">[22]</xref>&#x000a0;Studies have not determined the survival benefit of RT. Patients with node-positive disease may also receive RT. External beam RT with a chemo-sensitizing agent such as capecitabine or gemcitabine is typically used.<xref ref-type="bibr" rid="article-22032.r23">[23]</xref></p>
        <p>
<bold>Unresectable Disease</bold>
</p>
        <p>RT&#x000a0;may be used in unresectable disease&#x000a0;to provide local control and symptom relief.<xref ref-type="bibr" rid="article-22032.r21">[21]</xref>&#x000a0;Both external beam RT and stereotactic body radiation therapy (SBRT) may be employed.&#x000a0;SBRT allows very high doses of radiation to target lesions with a high degree of accuracy and provides local control rates that appear to be better than conventional fractionated external beam RT. RT is almost always administered with concurrent radiosensitizing chemotherapy. Typical doses in this setting are higher than those in adjuvant therapy.&#x000a0;</p>
      </sec>
      <sec id="article-22032.s13" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>
<bold>Adjuvant Therapy</bold>
</p>
        <p>Postoperative therapy should be offered within 8 to 12 weeks and requires baseline laboratory tests and imaging before therapy initiation. Adjuvant treatment may be delayed in cases where there are significant surgical complications or because of other patient-related factors that may impair chemotherapy tolerance. In general, the efficacy of adjuvant therapy decreases as the time to initiation increases. After resection, adjuvant therapy should be offered to patients with positive surgical margins, positive lymph nodes, or vascular involvement. The role of adjuvant chemotherapy in patients with completely resected specimens with microscopically negative margins is unclear. The benefit of adjuvant therapy is based on 2 trials, including the BILCAP trial and a randomized trial from Japan, which used single-agent adjuvant treatment. In the BILCAP trial, adjuvant capecitabine improved overall survival without chemotherapy, although this trend was not statistically significant.<xref ref-type="bibr" rid="article-22032.r24">[24]</xref>&#x000a0;Adjuvant treatment is currently accepted as a standard of care after resection. However, 2 trials have reported no benefit to gemcitabine-based regimens, which are presently discouraged. Most trials of systemic therapy combine gallbladder carcinoma with all biliary tract cancers. As gallbladder carcinoma has a higher rate of distant metastatic disease than other biliary tract cancers, chemotherapy may likely have additional benefits in these patients.<xref ref-type="bibr" rid="article-22032.r25">[25]</xref><xref ref-type="bibr" rid="article-22032.r26">[26]</xref><xref ref-type="bibr" rid="article-22032.r25">[25]</xref></p>
        <p>
<bold>Neoadjuvant Chemotherapy</bold>
</p>
        <p>Neoadjuvant chemotherapy is currently used in borderline resectable tumors and is a 2B recommendation in NCCN guidelines. Some patients may have an adequate response that allows for subsequent resection. For patients with upfront resectable disease, the routine use of neoadjuvant chemotherapy is not supported by evidence.<xref ref-type="bibr" rid="article-22032.r27">[27]</xref></p>
        <p>
<bold>Locally Advanced or Metastatic Disease</bold>
</p>
        <p>Chemotherapy can significantly extend survival in patients with metastatic disease. More recently, immunotherapy has improved this benefit. Based on the recent Topaz-1 trial, the combination of durvalumab with gemcitabine and cisplatin was superior to gemcitabine and cisplatin alone.<xref ref-type="bibr" rid="article-22032.r28">[28]</xref>&#x000a0;Pembrolizumab, in combination with gemcitabine and cisplatin, has also been shown to be superior to chemotherapy alone. In general, these are considered the standard of care.<xref ref-type="bibr" rid="article-22032.r29">[29]</xref>&#x000a0;Chemotherapy alone remains the standard of care in several settings where immunotherapy may not be available.&#x000a0;Multiple second- and third-line regimens exist for patients with poor performance status, persistent hyperbilirubinemia, or other considerations. With the identification of an increased number of specific tumor mutations and the availability of targeted agents, several targeted agents are now available based on the tumor mutational profile of these cancers.<xref ref-type="bibr" rid="article-22032.r30">[30]</xref></p>
      </sec>
      <sec id="article-22032.s14" sec-type="Staging">
        <title>Staging</title>
        <p>The National Comprehensive Cancer Network (NCCN) guideline, based on the American Joint Committee on Cancer, 8th edition, provides the following tumor, node, and metastasis (TNM) classification for gallbladder carcinoma:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>T</bold> (primary tumor)
<list list-type="bullet"><list-item><p><bold>TX</bold>: Primary tumor cannot be assessed</p></list-item><list-item><p><bold>T0</bold>: No evidence of primary tumor</p></list-item><list-item><p><bold>Tis</bold>: Carcinoma in situ</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>T1</bold>:&#x000a0;Tumor invades lamina propria or muscular layer
<list list-type="bullet"><list-item><p><bold>T1a:</bold> Tumor invades lamina propria</p></list-item><list-item><p><bold>T1b:</bold> Tumor invades muscle layer</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>T2</bold>:&#x000a0;Tumor invades the perimuscular connective tissue on the peritoneal side, without the involvement of the serosa (visceral peritoneum) OR tumor invades the perimuscular connective tissue on the hepatic side, with no extension into the liver&#x000a0;
<list list-type="bullet"><list-item><p><bold>T2a</bold>: Tumor invades the perimuscular connective tissue on the peritoneal side, without the involvement of the serosa (visceral peritoneum)</p></list-item><list-item><p><bold>T2b</bold>: Tumor invades the perimuscular connective tissue on the hepatic side, with no extension into the liver</p></list-item><list-item><p><bold>T3</bold>: Tumor perforates the serosa (visceral peritoneum) and/or directly invades the liver and/or 1 other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts</p></list-item><list-item><p><bold>T4</bold>:&#x000a0;Tumor invades main portal vein or hepatic artery or invades 2&#x000a0;or more extrahepatic organs or structures</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>N</bold>&#x000a0;(regional lymph nodes)
<list list-type="bullet"><list-item><p><bold>NX</bold>: Regional lymph nodes cannot be assessed</p></list-item><list-item><p><bold>N0</bold>:&#x000a0;No regional lymph node metastasis</p></list-item><list-item><p><bold>N1</bold>:&#x000a0;Metastases to 1 to 3 regional lymph nodes</p></list-item><list-item><p><bold>N2</bold>:&#x000a0;Metastases to &#x02265;4 or more regional lymph nodes</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>M</bold> (distant metastasis)
<list list-type="bullet"><list-item><p><bold>M0</bold>: No distant metastasis</p></list-item><list-item><p><bold>M1</bold>: Distant metastasis&#x000a0;<xref ref-type="bibr" rid="article-22032.r3">[3]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>American Joint Committee on Cancer Prognostic Groups</bold>
</p>
        <p>The following gallbladder carcinoma stages can be determined based on the TMN parameters:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stage 0</bold>: Tis; N0; M0</p>
          </list-item>
          <list-item>
            <p><bold>Stage I</bold>: T1; N0; M0</p>
          </list-item>
          <list-item>
            <p><bold>Stage II</bold>
<list list-type="bullet"><list-item><p>IIA: T2a; N0; M0</p></list-item><list-item><p>IIB: T2b; N0; M0</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Stage III</bold>
<list list-type="bullet"><list-item><p>IIIA: T3; N0; M0</p></list-item><list-item><p>IIIB: T1 to T3; N1; M0</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Stage IV</bold>
<list list-type="bullet"><list-item><p>IVA: T4; N0 to N1; M0</p></list-item><list-item><p>IVB: Any T; N2; and M0 or any T; any N; and M1&#x000a0;<xref ref-type="bibr" rid="article-22032.r3">[3]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22032.s15" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for gallbladder cancer is generally poor, with a 5-year overall survival of less than 20%. Unfortunately, most cases are diagnosed when&#x000a0;unresectable. According to the American Cancer Society statistics, the 5-year survival for localized disease is 69%, for regional metastatic disease is 28%, and for distant metastatic disease, 3%.<xref ref-type="bibr" rid="article-22032.r3">[3]</xref> T1a tumors that are entirely resected have a nearly 100% 5-year survival.</p>
      </sec>
      <sec id="article-22032.s16" sec-type="Complications">
        <title>Complications</title>
        <p>Complications from&#x000a0;gallbladder carcinoma&#x000a0;can be related to the disease itself or due to therapeutic interventions. Please see StatPearls' companion resources, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/94124">Cancer Chemotherapy</ext-link>" and "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/28189">Adverse Effects of Radiation Therapy</ext-link>," for more information on therapeutic complications.</p>
      </sec>
      <sec id="article-22032.s17" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Gallbladder carcinoma is a rare but aggressive cancer that often has a delayed presentation due to its silent progression. Patients with large gallstones or polyps, chronic cholecystitis, or other high-risk lesions should seek medical evaluation. Treatment involves surgery, chemotherapy, and sometimes radiation. After surgery, adjuvant therapy aims to prevent recurrence. Regular follow-up appointments and imaging scans are crucial to monitor for any signs of recurrence. Clinical trials may offer additional treatment options. Support from an interprofessional team and access to resources for psychosocial needs are essential for coping with the challenges of this diagnosis. Early detection and comprehensive care strategies can improve outcomes and quality of life for patients with gallbladder adenocarcinoma.</p>
      </sec>
      <sec id="article-22032.s18" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Healthcare professionals must possess clinical expertise to diagnose and treat gallbladder adenocarcinoma accurately. Strategic planning ensures timely interventions and optimal patient outcomes. Responsibilities include delivering compassionate care, advocating for patients, and promoting safety. Interprofessional communication fosters collaboration among physicians, advanced practitioners, nurses, pharmacists, and others, enhancing care coordination and patient-centeredness. As a cancer that has a poor prognosis, enrolling patients in clinical trials and providing them with pathways to accessing the most advanced available care will help advance the field and improve survival. By synergizing skills, strategy, ethics, responsibilities, communication, and coordination, healthcare teams can optimize patient care, safety, and outcomes in the challenging landscape of gallbladder adenocarcinoma management.</p>
      </sec>
      <sec id="article-22032.s19">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22032&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22032">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/gallbladder-carcinoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22032">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22032/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22032">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22032.s20">
        <fig id="article-22032.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Porcelain Gallbladder. This x-ray image demonstrates the inner gallbladder wall encrusted with calcium. Contributed by S Munakomi, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="porcelain" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22032.s21">
        <fig id="article-22032.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Gallbladder Adenomyomatosis. Gallbladder adenomyomatosis on a background of chronic cholecystitis. Note the multiple Rokitansky-Aschoff sinuses mixed with smooth muscle fibers. Patho, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://commons.wikimedia.org/w/index.php?search=Gallbladder+Adenomyomatosis&#x00026;title=Special:MediaSearch&#x00026;go=Go&#x00026;type=image">Public Domain</ext-link>, via Wikimedia Commons</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Gallbladder__adenomyomatosis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22032.s22">
        <fig id="article-22032.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Gallbladder Carcinoma. Computed tomography image demonstrating a gallbladder neoplasm. Contributed by S Lange, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gb" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22032.s23">
        <fig id="article-22032.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Gallbladder Stone. An abdominal ultrasound showing a large gall bladder stone of 2 cm in diameter with no dilation of the common bile duct or the biliary system. Contributed by S El-Nakeep, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Question__-__ERCP" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22032.s24">
        <title>References</title>
        <ref id="article-22032.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cancer Statistics, 2017.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-30</page-range>
            <pub-id pub-id-type="pmid">28055103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goetze</surname>
                <given-names>TO</given-names>
              </name>
            </person-group>
            <article-title>Gallbladder carcinoma: Prognostic factors and therapeutic options.</article-title>
            <source>World J Gastroenterol</source>
            <year>2015</year>
            <month>Nov</month>
            <day>21</day>
            <volume>21</volume>
            <issue>43</issue>
            <fpage>12211</fpage>
            <page-range>12211-7</page-range>
            <pub-id pub-id-type="pmid">26604631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benson</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>D'Angelica</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Abbott</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anaya</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Anders</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Are</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bachini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Binder</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Borad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bowlus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Burgoyne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Castellanos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chahal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cloyd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Covey</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Glazer</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jennings</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Raman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ronnekleiv-Kelly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sahai</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Turk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vauthey</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Venook</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Yopp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McMillian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schonfeld</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hochstetler</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>NCCN Guidelines&#x000ae; Insights: Biliary Tract Cancers, Version 2.2023.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>21</volume>
            <issue>7</issue>
            <fpage>694</fpage>
            <page-range>694-704</page-range>
            <pub-id pub-id-type="pmid">37433432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Araya</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Villaseca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Aretxabala</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Riedemann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Endoh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Roa</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression.</article-title>
            <source>Gastroenterology</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>111</volume>
            <issue>1</issue>
            <fpage>232</fpage>
            <page-range>232-6</page-range>
            <pub-id pub-id-type="pmid">8698204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alshahri</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Abounozha</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Best evidence topic: Does the presence of a large gallstone carry a higher risk of gallbladder cancer?</article-title>
            <source>Ann Med Surg (Lond)</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>61</volume>
            <fpage>93</fpage>
            <page-range>93-96</page-range>
            <pub-id pub-id-type="pmid">33425346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Katelaris</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Education and imaging. Gastrointestinal: Porcelain gallbladder.</article-title>
            <source>J Gastroenterol Hepatol</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>648</fpage>
            <pub-id pub-id-type="pmid">25776955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarici</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Duzgun</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Gallbladder polypoid lesions &#x0003e;15mm as indicators of T1b gallbladder cancer risk.</article-title>
            <source>Arab J Gastroenterol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>156</fpage>
            <page-range>156-158</page-range>
            <pub-id pub-id-type="pmid">28958638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Strategy for discriminating cholesterol and premalignancy in polypoid lesions of the gallbladder: a single-centre, retrospective cohort study.</article-title>
            <source>ANZ J Surg</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>89</volume>
            <issue>4</issue>
            <fpage>388</fpage>
            <page-range>388-392</page-range>
            <pub-id pub-id-type="pmid">30497105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akki</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Panarelli</surname>
                <given-names>NC</given-names>
              </name>
            </person-group>
            <article-title>Systematic Selective Sampling of Cholecystectomy Specimens Is Adequate to Detect Incidental Gallbladder Adenocarcinoma.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>1668</fpage>
            <page-range>1668-1673</page-range>
            <pub-id pub-id-type="pmid">31464710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Global, regional, and national burden and trends analysis of gallbladder and biliary tract cancer from 1990 to 2019 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2019.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2024</year>
            <volume>11</volume>
            <fpage>1384314</fpage>
            <pub-id pub-id-type="pmid">38638933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update.</article-title>
            <source>World J Gastroenterol</source>
            <year>2017</year>
            <month>Jun</month>
            <day>14</day>
            <volume>23</volume>
            <issue>22</issue>
            <fpage>3978</fpage>
            <page-range>3978-3998</page-range>
            <pub-id pub-id-type="pmid">28652652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giraldo</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Drill</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Satravada</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Dika</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Brannon</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Dermawan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mohanty</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ozcan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chakravarty</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Benayed</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vakiani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abou-Alfa</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Kundra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Ladanyi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>O'Reilly</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Jarnagin</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Vanderbilt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Basturk</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Arcila</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention.</article-title>
            <source>Clin Cancer Res</source>
            <year>2022</year>
            <month>Dec</month>
            <day>15</day>
            <volume>28</volume>
            <issue>24</issue>
            <fpage>5359</fpage>
            <page-range>5359-5367</page-range>
            <pub-id pub-id-type="pmid">36228155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roa</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Basturk</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Adsay</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Dysplasia and carcinoma of the gallbladder: pathological evaluation, sampling, differential diagnosis and clinical implications.</article-title>
            <source>Histopathology</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>79</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-19</page-range>
            <pub-id pub-id-type="pmid">33629395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bosch</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Truong</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Gallbladder carcinoma and epithelial dysplasia: Appropriate sampling for histopathology.</article-title>
            <source>Ann Diagn Pathol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>37</volume>
            <fpage>7</fpage>
            <page-range>7-11</page-range>
            <pub-id pub-id-type="pmid">30216818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prasad</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sikora</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Saxena</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>VK</given-names>
              </name>
            </person-group>
            <article-title>Mirizzi syndrome and gallbladder cancer.</article-title>
            <source>J Hepatobiliary Pancreat Surg</source>
            <year>2006</year>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>323</fpage>
            <page-range>323-6</page-range>
            <pub-id pub-id-type="pmid">16858544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Furlan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferris</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Hosseinzadeh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Borhani</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Gallbladder carcinoma update: multimodality imaging evaluation, staging, and treatment options.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>191</volume>
            <issue>5</issue>
            <fpage>1440</fpage>
            <page-range>1440-7</page-range>
            <pub-id pub-id-type="pmid">18941083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strom</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Maislin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Herlyn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rodriguez-Martinez</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Rios-Dalenz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Iliopoulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Soloway</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Serum CEA and CA 19-9: potential future diagnostic or screening tests for gallbladder cancer?</article-title>
            <source>Int J Cancer</source>
            <year>1990</year>
            <month>May</month>
            <day>15</day>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>821</fpage>
            <page-range>821-4</page-range>
            <pub-id pub-id-type="pmid">2335386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kalayarasan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Javed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nag</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>The role of staging laparoscopy in primary gall bladder cancer--an analysis of 409 patients: a prospective study to evaluate the role of staging laparoscopy in the management of gallbladder cancer.</article-title>
            <source>Ann Surg</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>258</volume>
            <issue>2</issue>
            <fpage>318</fpage>
            <page-range>318-23</page-range>
            <pub-id pub-id-type="pmid">23059504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butte</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>G&#x000f6;nen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>D'Angelica</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Kingham</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Fong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dematteo</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Blumgart</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jarnagin</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>The role of laparoscopic staging in patients with incidental gallbladder cancer.</article-title>
            <source>HPB (Oxford)</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>463</fpage>
            <page-range>463-72</page-range>
            <pub-id pub-id-type="pmid">21689230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuks</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Regimbeau</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pessaux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bachellier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Raventos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mantion</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gigot</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Chiche</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pascal</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Azoulay</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Laurent</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Letoublon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boleslawski</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rivoire</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mabrut</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Adham</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le Treut</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Delpero</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ayav</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boudjema</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nuzzo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Scotte</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farges</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Is port-site resection necessary in the surgical management of gallbladder cancer?</article-title>
            <source>J Visc Surg</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>150</volume>
            <issue>4</issue>
            <fpage>277</fpage>
            <page-range>277-84</page-range>
            <pub-id pub-id-type="pmid">23665059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Apisarnthanarax</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Czito</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>DeMatteo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Drinane</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hallemeier</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Koay</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Lasley</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pursley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schaub</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Venepalli</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Zibari</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cardenes</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline.</article-title>
            <source>Pract Radiat Oncol</source>
            <year>2022</year>
            <season>Jan-Feb</season>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-51</page-range>
            <pub-id pub-id-type="pmid">34688956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben-Josef</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guthrie</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>El-Khoueiry</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Corless</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Zalupski</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lowy</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Alberts</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Micetich</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Blanke</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.</article-title>
            <source>J Clin Oncol</source>
            <year>2015</year>
            <month>Aug</month>
            <day>20</day>
            <volume>33</volume>
            <issue>24</issue>
            <fpage>2617</fpage>
            <page-range>2617-22</page-range>
            <pub-id pub-id-type="pmid">25964250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ilyas</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hallemeier</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Gores</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Cholangiocarcinoma - evolving concepts and therapeutic strategies.</article-title>
            <source>Nat Rev Clin Oncol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>95</fpage>
            <page-range>95-111</page-range>
            <pub-id pub-id-type="pmid">28994423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Primrose</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>HZ</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mirza</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Anthony</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Corrie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Finch-Jones</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wasan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wall</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wadsley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>JTR</given-names>
              </name>
              <name>
                <surname>Stocken</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Praseedom</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Neoptolemos</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Iveson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Raftery</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Garden</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Stubbs</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Bridgewater</surname>
                <given-names>J</given-names>
              </name>
              <collab>BILCAP study group</collab>
            </person-group>
            <article-title>Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.</article-title>
            <source>Lancet Oncol</source>
            <year>2019</year>
            <month>May</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>663</fpage>
            <page-range>663-673</page-range>
            <pub-id pub-id-type="pmid">30922733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rizzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brandi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care.</article-title>
            <source>Expert Rev Gastroenterol Hepatol</source>
            <year>2021</year>
            <month>May</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>483</fpage>
            <page-range>483-485</page-range>
            <pub-id pub-id-type="pmid">33307876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamarca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Edeline</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McNamara</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Hubner</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Nagino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bridgewater</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Primrose</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Current standards and future perspectives in adjuvant treatment for biliary tract cancers.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>84</volume>
            <fpage>101936</fpage>
            <pub-id pub-id-type="pmid">31986437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rizzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brandi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.</article-title>
            <source>Cancer Treat Res Commun</source>
            <year>2021</year>
            <volume>27</volume>
            <fpage>100354</fpage>
            <pub-id pub-id-type="pmid">33756174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ebia</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Sankar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Osipov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hendifar</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>TOPAZ-1: a new standard of care for advanced biliary tract cancers?</article-title>
            <source>Immunotherapy</source>
            <year>2023</year>
            <month>May</month>
            <volume>15</volume>
            <issue>7</issue>
            <fpage>473</fpage>
            <page-range>473-476</page-range>
            <pub-id pub-id-type="pmid">36950948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Almhanna</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Immune checkpoint inhibitors in combination with chemotherapy for patients with biliary tract cancer: what did we learn from TOPAZ-1 and KEYNOTE-966.</article-title>
            <source>Transl Cancer Res</source>
            <year>2024</year>
            <month>Jan</month>
            <day>31</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-24</page-range>
            <pub-id pub-id-type="pmid">38410206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22032.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelley</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Bridgewater</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gores</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>AX</given-names>
              </name>
            </person-group>
            <article-title>Systemic therapies for intrahepatic cholangiocarcinoma.</article-title>
            <source>J Hepatol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>353</fpage>
            <page-range>353-363</page-range>
            <pub-id pub-id-type="pmid">31954497</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
